Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2020-03-27 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
关于公司产品获得美国FDA紧急使用授权的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the FDA Emergency Use Authorization (EUA) for a COVID-19 nucleic acid testing kit. It provides details about the product, its market situation, and the impact and risks related to this authorization. The document is relatively short (1917 characters) and does not contain financial statements, management discussion, or detailed financial data. It is an official announcement about a regulatory approval related to the company's product, not a financial report or earnings release. Therefore, it fits best into the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2020-03-27 Chinese
关于控股子公司取得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (1003 characters) from Shenzhen BGI Genomics Co., Ltd. about its controlling subsidiary obtaining a medical device registration certificate issued by the Beijing Drug Administration. It describes the product, registration details, market situation, and potential impact on the company. There is no financial data, no mention of a report being attached or published, and no regulatory certification or officer attestation. The content is an official announcement about a regulatory approval related to the company's product line, which does not fit into financial reports, management changes, or other specific categories. It is a regulatory announcement about a business development event. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2020-03-25 Chinese
关于股东减持股份计划的预披露公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement by Shenzhen BGI Genomics Co., Ltd. regarding a planned reduction in shareholding by shareholders holding more than 5% of the company's shares. It details the shareholders involved, the number and percentage of shares to be reduced, the reasons for reduction, the method and timing of the reduction, and related commitments and risk disclosures. The document does not contain financial statements, earnings data, or detailed financial analysis. It is a disclosure about a shareholder's intention to sell shares, which fits the category of a Major Shareholding Notification or a related shareholding change announcement. Given the content focuses on a shareholder's plan to reduce holdings and complies with regulatory disclosure requirements, the appropriate classification is Major Shareholding Notification (MRQ). The document length is 3587 characters, which is consistent with a detailed announcement but not a full financial report or regulatory filing of other types.
2020-03-20 Chinese
关于公司产品在美国申报EUA暨启动临床商业销售的说明公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Shenzhen BGI Genomics Co., Ltd. regarding the status of their product's Emergency Use Authorization (EUA) application with the U.S. FDA and the initiation of clinical commercial sales in the U.S. It details the product information, regulatory background, current market situation, and risk factors. The document is relatively short (2183 characters) and serves as an update on regulatory and commercial status rather than a financial report or detailed regulatory filing. It does not contain financial statements, audit information, or detailed management discussion. It is not a report itself but an announcement about regulatory progress and commercial sales initiation. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-03-18 Chinese
独立董事关于第二届董事会第十八次会议相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is an opinion statement from independent directors regarding a specific board meeting agenda item about related-party transactions involving guarantees for a bond issuance. It references regulatory guidelines and company bylaws, and it is a pre-approval or endorsement opinion rather than a full report or financial statement. The content focuses on board/management information related to governance and internal approvals. The document length is short (696 characters), and it does not contain financial data or detailed financial results. Therefore, it fits best under Board/Management Information (MANG).
2020-03-17 Chinese
独立董事关于第二届董事会第十八次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from independent directors regarding matters discussed at the 18th meeting of the second board of directors. It focuses on opinions about guarantees provided by subsidiaries and related parties for the company's public bond issuance. The content is about board-level decisions and opinions on corporate governance and related-party transactions, not a full financial report or earnings release. The document length is short (1047 characters) and it is a formal opinion related to board matters, not a report or announcement of voting results. Therefore, it fits best under Board/Management Information (MANG).
2020-03-17 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.